New imaging method for cancer using a dual targeting PET radiotracer
68Ga-FAP-RGD PET/CT : Dosimetry and Preliminary Clinical Translational Studies in Cancer Patients
This study is testing a new imaging method for cancer using a special tracer to see if it works better than current options in helping doctors find and treat different types of cancer.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | First Affiliated Hospital of Fujian Medical University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT05515783 on ClinicalTrials.gov |
What this trial studies
This study evaluates the safety, biodistribution, and radiation dosimetry of a novel dual targeting PET radiotracer, 68Ga-FAP-RGD, in patients with various types of cancer. It aims to compare the imaging results of 68Ga-FAP-RGD with those of existing tracers, 68Ga-FAPI-02 and 18F-FDG, to assess its diagnostic efficacy. The research focuses on the role of fibroblast activation protein and integrin αvβ3 in cancer imaging and treatment. By analyzing the pharmacokinetics and dosimetry, the study seeks to enhance cancer imaging techniques and improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include patients with various solid tumors who have available histopathological findings.
Not a fit: Patients who are pregnant, lactating, or have severe hepatic and renal insufficiency may not benefit from this study.
Why it matters
Potential benefit: If successful, this could provide a more effective imaging method for diagnosing and monitoring various cancers.
How similar studies have performed: Other studies have shown promising results with similar dual targeting approaches, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Various solid tumors with available histopathological findings * Signed informed consent Exclusion Criteria: * pregnant or lactational women * who suffered from severe hepatic and renal insufficiency
Where this trial is running
Fuzhou, Fujian
- Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Study coordinator: Weibing Miao, MD
- Email: miaoweibing@126.com
- Phone: 86-0591-87981618
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.